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OBJECTIVES We sought to evaluate the relative effects of low doses of pravastatin (20 mg/day) and
simvastatin (10 mg/day) on indices of cardiac allograft rejection. We further examined the
relative efficacy and safety of these two drugs on lipid-lowering in heart transplantation.
BACKGROUND The immunomodulatory effects of hydroxy methyl glutaryl-coenzyme A reductase inhibitors
have been increasingly recognized. Previous studies have demonstrated an ameliorative
influence of pravastatin on hemodynamically compromising rejection after heart transplan-
tation. A recent observational trial suggested that simvastatin 20 mg/day was associated with
trends to lower survival and more adverse effects than pravastatin 40 mg/day.
METHODS In a 12-month prospective, open-label study, 50 heart transplant recipients received either
open-label pravastatin 20 mg daily (n  24) or simvastatin 10 mg daily (n  26) within four
weeks of transplantation. Indices of allograft rejection including treated rejection, rejection
with hemodynamic compromise, noncellular rejection, and mean one-year biopsy score were
compared between the two cohorts, as well as with a statin-naive control population (n 37).
Lipid levels, safety, and post-transplant outcomes were also assessed as secondary end points.
RESULTS We found no significant differences in any allograft rejection parameter between the two
groups. However, total low-density lipoprotein (LDL), but not high-density lipoprotein
cholesterol or triglycerides, were lower in the simvastatin arm (23% vs. 11%, p  0.02).
No cases of rhabdomyolysis or myositis occurred in either group. Survival at one year was
similar in both treatment groups (91% for patients on pravastatin and 92% for patients on
simvastatin). Both groups had better survival compared with the statin-naive control group
(80%, p  0.04).
CONCLUSIONS Simvastatin (10 mg/day) and pravastatin (20 mg/day) are associated with similar beneficial
effects on cardiac allograft rejection and one-year survival. At these doses, simvastatin
decreases LDL cholesterol more so than pravastatin with no increase in adverse effects in
heart transplantation. (J Am Coll Cardiol 2002;40:1609–14) © 2002 by the American
College of Cardiology Foundation
The emergence of hydroxy methyl glutaryl-coenzyme A
(HMG-CoA) reductase inhibitors (statins) has ushered in
an era of widespread acceptance for lipid-lowering in heart
transplant and in cardiac disease, largely because of their
potent effects (1). It has become increasingly apparent that
statins exert their beneficial effects on coronary artery
disease by a host of pleiotropic effects that involve immu-
nomodulation (2). Exploitation of these immunologic ben-
efits in heart transplantation has been noted in a provocative
investigation by Kobashigawa et al. (3) wherein pravastatin
(40 mg/day) was shown to not only lessen cardiac rejection
associated with hemodynamic compromise but also improve
survival.
Whether these salutary effects are unique to pravastatin or
shared by other members of this drug class remains contro-
versial. A recent observational investigation by Keogh et al.
(4) comparing pravastatin (40 mg/day) with simvastatin (20
mg/day) alluded to a trend toward a better outcome with
pravastatin that was attributed to a more favorable immu-
nologic complication profile with pravastatin. Other data by
Wenke et al. (5) demonstrated that low-dose simvastatin
(10 mg/day) in the long term significantly improves survival
and lowers the incidence of cardiac allograft vasculopathy
with a tendency for fewer serious rejection episodes.
The purpose of our study was to primarily assess the
relative effects of low-dose simvastatin (10 mg/day) and
pravastatin (20 mg/day) on cardiac allograft rejection, con-
firm their lipid-lowering effects, determine safety, and
establish one-year clinical outcomes.
METHODS
Patients. All consecutive adult (18 years) primary heart
transplant recipients between 1995 and 1998 with sustained
elevations (on two consecutive and separate measurements)
of low-density lipoprotein (LDL) cholesterol (130 mg/dl)
within four weeks after heart transplantation were screened
for enrollment. Patients were excluded if they had any
contraindications to statin therapy, a prior history of myop-
athy or rhabdomyolysis, or renal failure requiring chronic
dialysis.
Intervention. The patients were randomly treated with
either pravastatin 20 mg/day (n  24) or simvastatin 10
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mg/day (n  26) for at least one year. In addition, all
patients underwent dietary counseling from a nutritionist to
follow a low-fat diet. The primary immunoprophylaxis
regimen included cyclosporine (microemulsion), azathio-
prine, and corticosteroids in accordance with the institu-
tional protocol as indicated elsewhere. A statin-naive group
of 37 heart transplant recipients were used to compare
outcomes with the statin therapy group. This group was
assembled as a parallel cohort in whom the transplant
cardiologist chose not to prescribe lipid-lowering therapy.
The statin-naive group consisted of parallel cohort trans-
planted during the same period as the treatment cohort but
in whom the transplant cardiologist felt that lipid-lowering
therapy was not mandatory owing to lower baseline lipid
levels.
Cardiac allograft rejection. Serial surveillance endomyo-
cardial biopsies were obtained at predetermined temporal
frequencies. Endomyocardial biopsies were performed at
weeks 1, 2, 3, 4, 6, 8, 10, and 12, then at months 4, 5, 6, 9,
and 12. Rejection was treated where there was International
Society for Heart and Lung Transplantation grade 3A
rejection or higher or a lower grade in the presence of
hemodynamic compromise. Treated episodes of cellular
rejection (grade 3A), rejection with hemodynamic com-
promise (any cellular infiltrate1A; left ventricular ejection
fraction decrease by 20%, cardiac index decrease or pulmo-
nary capillary wedge pressure increase by 25% from base-
line), and noncellular rejection (hemodynamic compromise
in the absence of a cellular infiltrate or positive tissue
immunofluorescence) were definitions used to quantify al-
lograft rejection. Furthermore, a one-year mean biopsy
rejection score to account for clinical and subclinical rejec-
tion was also assessed as previously reported by our group
(6). We also compared the biopsy score findings in each
group with the parallel statin-naive cohort.
Lipid-lowering efficacy and safety. Detailed fasting lipid
profiles, hepatic function tests (serum alkaline phosphatase,
serum aspartate aminotransferase, serum alanine amino-
transferase, and serum bilirubin), and serum creatinine
phosphokinase were obtained at fortnightly intervals during
the first month after initiation of treatment and then at
three monthly intervals. Elevation of alanine aminotrans-
ferase levels to more than 3 times the normal level and
creatinine phosphokinase to more than 10 times the normal
level were considered abnormal and a side effect of statin
therapy. In addition, clinical evaluations for development of
adverse effects were routinely performed in all the patients
by monthly clinical visits. Drug compliance and withdrawals
were also assessed. Concomitant use of cytochrome p450
inhibitors was prohibited for the duration of the trial.
Clinical outcomes. One-year all-cause survival was com-
puted for the study group with cause of death recorded.
Although surveillance angiography was performed in all
survivors at one year, the data were not analyzed because it
was felt that the one-year time point using angiography was
too short to make any meaningful conclusions regarding
cardiac allograft vasculopathy. Intravascular ultrasound was
not routinely performed in the patient cohort.
Statistical analysis. Comparisons of baseline characteris-
tics and six-month data between groups were performed
using the unpaired Student t test for continuous variables
and chi-square analysis or Fisher exact test (if the expected
frequency was smaller than five) as appropriate for categor-
ical variables. Changes in indices of allograft rejection and
lipids over time were examined by paired Student t tests.
The Pearson product-moment correlation coefficient was
used to evaluate the relationship between the degree of
LDL cholesterol lowering and the mean biopsy rejection
score. All data are presented as mean  SD. Significance
was set at p  0.05.
RESULTS
Patients and statin dose. Fifty transplant recipients met
the inclusion criteria for enrollment. The study cohort
consisted of 39 men and 11 women (mean recipient age 53
 9 years, donor age 26  11 years). The mean dose of
pravastatin was 20  5 mg/day; the mean dose of simva-
statin was 11  6 mg/day. No differences in immunosup-
pression were noted in the two groups. Additionally, there
were no baseline differences between the two groups with
regard to age, race, gender, status at time of transplantation,
ischemic time, human leukocyte-antigen matches, or im-
munosuppression used. Compared with the treatment
group, the statin-naive patients shared the same baseline
characteristics except for lower lipid levels at inception and
higher nonischemic etiology of heart failure at time of
transplantation (Table 1).
Cardiac allograft rejection. Simvastatin- and pravastatin-
treated heart transplant recipients had no significant differ-
ences in the rates of treated cellular rejection (11% vs. 8.3%),
rejections with hemodynamic compromise (11% vs. 12.5%),
noncellular rejection (7.6% vs. 0%), or the sum of cellular
and noncellular rejection (27% vs. 25%). In addition, the
one-year mean biopsy rejection score was also similar in
both groups (0.78  0.03 vs. 0.74  0.04). Compared with
a parallel “statin-naive” cohort of 37 patients, both
simvastatin- and pravastatin-treated patients exhibited sig-
nificantly lower mean biopsy scores (0.96  0.05, p  0.05
compared with simvastatin and pravastatin groups) (Figs. 1
and 2).
Lipid variables. BASELINE LIPIDS. Baseline total choles-
terol levels were similar in the two study groups (243  46
mg/dl in the pravastatin group vs. 257  49 mg/dl in the
Abbreviations and Acronyms
HDL  high-density lipoprotein
HMG-CoA  hydroxy methyl glutaryl-coenzyme A
LDL  low-density lipoprotein
MHC  major histocompatability complex
NO  nitric oxide
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simvastatin group); initial LDL cholesterol was 154  56
mg/dl in the pravastatin group and 167  53 mg/dl in the
simvastatin group; starting triglyceride levels were also
similar in the two study groups (200  120 mg/dl in the
pravastatin group vs. 193  94 mg/dl in the simvastatin
group); and the high-density lipoprotein (HDL) cholesterol
levels were also no different between the groups (38  6
mg/dl vs. 39  8 mg/dl) (all p  NS).
ABSOLUTE CHANGES AT 12 MONTHS. The total cholesterol
levels at 12 months of treatment were 218  54 mg/dl in
the pravastatin group (p 0.01) and 204 41 mg/dl in the
simvastatin group (p 0.01). The LDL cholesterol was 131
 47 mg/dl in the pravastatin group (p  0.05) and 120 
34 mg/dl in the simvastatin group (p  0.05). There was a
significant difference between the absolute reductions in
LDL cholesterol between the pravastatin and simvastatin
groups (p  0.01). Triglyceride levels were 186  97 mg/dl
in the pravastatin group and 185  113 mg/dl in the
simvastatin group (p  NS). Similarly, no significant
differences in HDL cholesterol elevations were noted
among the groups.
RELATIVE CHANGES AT 12 MONTHS. The percentage reduc-
tion in total cholesterol was 9.2% in the pravastatin group
compared with 18.8% in the simvastatin group (p  0.08).
Percentage reduction in LDL cholesterol was significantly
higher in the simvastatin group versus pravastatin (23.3% vs.
14.9%; p  0.04). The relative reductions in triglyceride
levels were similar in both the study groups (6.2% in the
pravastatin group vs. 8.1% in the simvastatin group; p 
NS). With regard to HDL cholesterol levels, only modest
increases were noted in the pravastatin versus simvastatin
groups (4%  3% vs. 6%  4%, p  NS).
CORRELATION OF LDL LOWERING AND ALLOGRAFT REJEC-
TION. No significant correlation of degree of LDL choles-
terol lowering and mean biopsy rejection score on linear
regression was identified (r  0.2, p  NS).
Adverse effects. At the study doses, no significant episodes
of transaminase elevation requiring drug withdrawal were
noted in either study group. No clinical or laboratory
evidence of myopathy or rhabdomyolysis was seen in the
study groups. No drug withdrawals occurred, and patient
compliance with drug regimens exceeded 97%.
One-year outcome. Similar 12-month survival was noted
among the simvastatin (92%) and pravastatin (91%) study
arms. The two deaths in the simvastatin arm were related to
a cerebrovascular accident and multi-organ failure in the
presence of systemic bacterial infection. The pravastatin
study arm included one death from septic shock and a
second attributable to the development of accelerated cor-
onary artery disease as noted on pathology. Compared with
both statin groups, the statin-naive group demonstrated
lower one-year survival (80%, p  0.04). Of seven deaths in
the control group, three deaths occurred as a result of
refractory allograft rejection with hemodynamic compro-
mise, two deaths were caused by septic shock, one was due
to cerebrovascular accident, and the remaining deaths were
attributed to coronary artery disease. Thus, five of seven
deaths could be attributed to “immunologic deaths.”







Recipient age (yrs) 52  10 54  6 53  9
Donor age (yrs) 29  12 31  10 31  11
Recipient gender 91% men 86% men 88% men
Donor gender 56% men 59% men 60%
Recipient race 78% white 76% white 74% white
Ischemic etiology 58% 55% 41%*
Urgent transplantation 51% 52% 56%
Number of HLA matches 0.9  1.1 0.6  0.7 0.9  0.9
Ischemic time (min) 177  65 179  33 181  26
Total cholesterol (mg/dl) 243  46 257  49 213  51*
LDL (mg/dl) 154  56 167  53 134  32*
HDL (mg/dl) 38  9 39  11 40  12
Triglycerides (mg/dl) 200  120 193  94 196  86
*p  0.05 compared with either pravastatin or simvastatin group.
HDL  high-density lipoprotein; HLA  human leukocyte-associated antigen;
LDL  low-density lipoprotein.
Figure 1. Rates of allograft rejection (%) between pravastatin (black bars) and simvastatin (white bars). HDC  hemodynamic compromise.
1611JACC Vol. 40, No. 9, 2002 Mehra et al.
November 6, 2002:1609–14 Statins and Heart Transplantation
DISCUSSION
Study findings. The results of our investigation suggest
that at low doses, immunologic outcomes are similar in
simvastatin- and pravastatin-treated heart transplant recip-
ients. Compared with statin-naive patients, both simvasta-
tin and pravastatin are associated not only with superior
rejection-related outcomes but also with one-year survival.
Although unexpected, simvastatin was noted to provide
better LDL cholesterol lowering than pravastatin; however,
this did not appear to influence first-year outcome.
Mechanisms of non–lipid-lowering statin effects. In ad-
dition to lipid-lowering effects, statins exhibit ubiquitous
vascular properties that include plaque stabilization, inhibi-
tion of smooth muscle cell proliferation, improved endothe-
lial function, and decreased inflammation (2). Statins in-
hibit HMG-CoA reductase, the enzyme that catalyzes the
conversion of 3-hydroxy-3-methylglutaryl-CoA to meval-
onate. In doing so, statins also reduce the downstream
products of mevalonate in the cholesterol synthesis pathway.
Two of these downstream products, farnesyl pyrophosphate
and geranylgeranyl pyrophosphate, are the lipid moieties
that can modulate the function of certain essential signaling
proteins that influence smooth muscle cells and generation
of nitric oxide (NO) (7). In particular, the small gera-
nylgeranyl transferase-binding protein, Rho, whose mem-
brane localization and activity are affected by post-
translational isoprenylation, may play an important role in
mediating the direct vascular effects of statins (8). Recent in
vitro studies have suggested that statins, by inhibiting the
farnesylation of Rho, may decrease smooth muscle prolif-
eration (9). In addition to inhibiting farnesylation, statins
have recently been shown to improve endothelial function,
vasomotor tone, and markers of inflammation by increasing
the availability of NO, providing another explanation for
their surprising allogeneic protective effects (8). Thus, statin
use may result in increased expression of endothelial NO
synthase and greater NO production (10). Kureishi et al.
(11) demonstrated that mevalonate, the product of HMG-
CoA reductase, inhibits a central signaling molecule,
phosphatidylinositol-3 kinase, which might result in up-
regulation of NO and improved vasomotor tone and endo-
thelial function.
Anti-inflammatory properties of statins. Accumulating
more evidence for an anti-inflammatory effect of statins
independent of their lipid-lowering effect, Jialal et al. (12)
have recently demonstrated that simvastatin, pravastatin,
and atorvastatin decrease high-sensitivity C-reactive protein
in a similar manner independent of their lipid-lowering
effects. In this study, the investigators were unable to
establish a link with interleukin-6 levels but did demon-
strate an association with triglycerides, a particularly potent
risk factor for outcomes after heart transplantation. Major
histocompatability complex (MHC) class II molecules are
directly involved in the control of the immune response.
During allograft implantation, the cells become MHC II
expressive. Kwak et al. (13) have demonstrated that statins
act as direct inhibitors of MHC II induced T-cell activa-
tion. This action is a result of the inhibition of the inducible
promoter IV of the class II transactivator. This effect may
form an important basis for the understanding of immuno-
modulation. Other properties of statins in transplantation
may bear note as modulators of allograft outcome. Hols-
chermann et al. (14) have reported the effects of low-dose
simvastatin on inhibiting expression of monocyte tissue
Figure 2. Comparison of average biopsy rejection scores. *p  0.05 for simvastatin or pravastatin group compared with statin-naive groups.
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factor and reduction in the hypercoagulability seen in
transplant recipients. This specific form of immunomodu-
lation might be protective for the late development of
allograft vasculopathy. Katznelson et al. (15) have studied
the effects of pravastatin on natural killer cell cytotoxicity.
These investigators have shown that pravastatin and cyclospor-
ine act synergistically to reduce cytotoxic T lymphocyte activ-
ity, suggesting that this specific effect is unique to transplant
recipients. More recently, Weis et al. (16) have demonstrated
improved endothelial function and reduced cytokine activation
in clinical heart transplantation with simvastatin.
Comparison with other studies. Several investigators have
consistently demonstrated a beneficial impact of the hydro-
philic statin, pravastatin, in heart transplantation as well as
renal transplantation. In particular, early post-transplant use
of this agent has been associated with a decrease in hemo-
dynamically compromising rejection, attenuation of a rise in
lipids, improved one-year survival, and trends in favor of a
reduction in allograft coronary artery disease (3). Wenke et
al. (5) have used simvastatin in low doses as in our
investigation, and suggested that in the long term at four
years the use of this agent improves outcomes as a conse-
quence of a reduction in significant coronary artery disease
after transplantation. More recently, Keogh et al. (4) have
reported their results of a nonrandomized observational trial
comparing pravastatin and simvastatin wherein they raised
caution that higher doses of simvastatin may be associated
with poor outcomes and more adverse effects. Our investi-
gation differs significantly from Keogh et al. (4) because we
used low doses of simvastatin, prohibited co-administration
of drugs that require metabolism through or inhibit the
cytochrome p450 pathway (other than cyclosporine), and
waited until the renal function in our patients stabilized
before initiating drug therapy. These sentinel differences
abrogated any significant clinical distinctions between prav-
astatin and simvastatin as demonstrated by no significant
cases of hepatotoxicity or muscle toxicity in our two patient
groups. Furthermore, our study also suggests that low doses
of statins may be sufficient to exert beneficial effects on
12-month outcome as evidenced by one-year survivals
exceeding 90% in both study groups.
Safety of low-dose simvastatin. Although Keogh et al. (4)
have raised concern about the safety of simvastatin, other
investigators have studied low-dose simvastatin (5 to 10
mg/day) and have demonstrated safety, tolerability, and
efficacy in lowering lipid abnormalities. An earlier study by
Vanhaecke et al. (17) administered low-dose simvastatin
(average dose 10 mg/day) in 26 heart transplant recipients
and demonstrated a decrease in cholesterol of 27% and
LDL cholesterol of 40%, much more impressive results than
in our cohort. Arnadottir et al. (18) conducted a double-
blind, randomized, placebo-controlled study with low-dose
simvastatin in 40 renal transplant recipients. No cases of
myopathy and creatinine kinase enzyme elevation were
reported in this study, similar to the findings of our
investigation. Nevertheless, it is important to remain cau-
tious in using simvastatin in the presence of other drugs
interactive with CYP3A4-dependent metabolic pathways.
The primary difference between simvastatin and pravastatin
in this regard relates to whether the drug is administered in
the lactone form (simvastatin) or in the active non-lactone
form (pravastatin). All lactone forms inhibit the cytochrome
enzyme pathways more than the acid forms, with pravasta-
tin having the least likelihood of significant interaction (19).
Study limitations. Several study limitations should be
taken into account during interpretation of these observa-
tions. The numbers of patients studied were small, and the
statin-naive group was not randomized as evidenced by
baseline differences in lipid perturbations. Although adverse
effects were not present with either simvastatin or pravasta-
tin in our relatively small study, our study may not have been
powered to detect infrequent, but potentially serious adverse
effects, particularly severe myopathy. Notwithstanding these
limitations, the observed findings allow comparisons be-
tween the two statin-treated groups and suggest that despite
lower baseline lipids in the statin-naive group, one-year
outcomes were better with either statin-treated group. This
lends credence to the potential benefit of statins in not only
abrogating rejection but also enhancing survival.
Conclusions. Simvastatin (10 mg/day) and pravastatin (20
mg/day) are associated with similar beneficial effects on
cardiac allograft rejection and one-year survival. At these
doses, simvastatin decreases LDL cholesterol more than
pravastatin with no increase in adverse effects in heart
transplantation.
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